Drug Profile

ALM 401

Alternative Names: EGFRXROR1 bispecifiic ADC; ALM-401; TSY-310

Latest Information Update: 13 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Almac Discovery
Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

06 May 2025 ALM 401 licensed to Formosa Pharmaceuticals in world
25 Apr 2025 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
06 Jun 2024 Almac Discovery has patents pending for Bi-specific binding molecules in the US

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com